Mostafa Norizadehtazehkand1* and Orkideh Hajipour2
1Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Zonguldak Bulent Ecevit University, Zonguldak, Turkey
2Department of Biology, Institute of Basic and Applied Sciences, Pamukkale University, Denizli, Turkey
*Corresponding Author: Mostafa Norizadehtazehkand, Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Zonguldak Bulent Ecevit University, Zonguldak, Turkey.
Received: February 06, 2020; Published: March 04, 2020
Coronavirus (Wuhan Coronavirus) is a type of virus which has RNA and determined by club like spikes of its surface. The virus is a pathogen virus and it can be infected humans and other animals. This study was aimed to design and analysis of multi epitope vaccine against Wuhan Coronavirus by different bioinformatics analysis and software’s. The vaxiJen score of these sequences were 0.4052, 0.4201, and 0.4371. The result of Allg Pred and Toxinpred showed that the vaccine does not have allergenic or toxic effect for human cells. The result obtained from Protparam showed that the molecular weight of vaccine is 48.68 kDa. The estimated half-life of multi epitope based vaccine was found to be greater than 20 hours in mammalian cells, greater than 30 hours in yeast cells, and greater than 10 hours in E.coli and the candidate vaccine is stable and soluble in water. The membrane helices value of vaccine was 17.73%. Ramachandran plot analysis supported the high quality structure of the refined model. The result of protein protein docking showed the maximum affinity of candidate vaccine to HLA-A0201, HLA - B2705, HLA-B5704, and HLA - B57037 with the score of -686.54,-709.05, - 633.53, and 642.61 respectively. The result of this research showed that our designed vaccine maybe stimulate B-Cells and different types of T-cells. However, the vaccine could be produced (in lab scale) and tested in laboratory animals.
Keywords: B-Cell; MHC Class I; Multi Epitope; Recombinant Vaccine; Wuhan Coronavirus
Citation: Mostafa Norizadehtazehkand and Orkideh Hajipour. “In silico Recombinant Vaccine Candidate Against Coronavirus (2019-nCoV)". Acta Scientific Microbiology 3.4 (2020): 17-23.
Copyright: © 2020 Mostafa Norizadehtazehkand and Orkideh Hajipour. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.